7,980
+0.63%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shinpoong Pharmaceutical Co
Its shares trade on KRX under the ticker 019170.KS. It has been listed since 20 January 1990. In the fiscal year to 31 December 2025, it reported revenue of ₩234.68bn and net income of ₩8.83bn. At that date it held total assets of ₩352.47bn and shareholders' equity of ₩269.98bn.
Shinpoong Pharmaceutical Co. Ltd. engages in the manufacture and sales of pharmaceutical products. The company is headquartered in Ansan, Gyeonggi-Do. The firm's product portfolio consists of antibiotics, cardiovascular drugs, anti-cancer drugs, psychoneurotic drugs, antirheumatic drugs, antidiabetics, antifungal agents, antihistamines, antiviral agents, benign prostatic hyperplasia (BPH) drugs and trichogens. The firm also provides active pharmaceutical ingredients (APIs) synthesized by the Company, including non-steroidal anti-inflammatory drugs (NSAIDs), cardiovascular drugs, anti-ulcer drugs, respiratory drugs, antispasmodics drugs and others. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Jan 1990
- Employees
- 840
- Website
- shinpoong.co.kr ↗
Leadership
Pay as last reported
- Mr. Je Man YooChief Executive Officer, Director, since 2014
- Mr. Ju Yeong SungManaging Director
- Ms. Cheong JooManaging Director
- Mr. Jin Gyu ParkAssistant Managing Director
- Mr. Hyeok Rae KimAssistant Managing Director
- Mr. Chung Hwan ParkAssistant Managing Director
- Mr. Jae Hong ParkAssistant Managing Director
- Mr. Jong Seok YimAssistant Managing Director
- Mr. Bon Jun GuNon-Executive Independent Director
- Mr. Seung Cheol HanNon-Executive Independent Director
- Mr. Jin Yeong JungNon-Executive Independent Director
- Mr. Dae Sin KangNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 63
- Social
- 57
- Governance
- 25
- Women in the workforce
- 34.74065%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong market presence and reputation: Shinpoong Pharmaceutical Co Ltd has established itself as a leading pharmaceutical company with a strong brand image.
- Diversified product portfolio: The company offers a wide range of products in various therapeutic areas, ensuring a balanced revenue stream.
- Robust research and development (R&D) capabilities: Shinpoong Pharma invests significantly in R&D activities, enabling the development of innovative and effective drugs.
- Growing global presence: The company has expanded its operations beyond domestic markets, tapping into international markets and increasing its customer base.
Weaknesses
- Dependence on specific product lines: Shinpoong Pharma's revenue heavily relies on a few key products, making it vulnerable to potential market fluctuations or patent expirations.
- Limited market share in certain regions: The company faces strong competition in certain geographic regions, hindering its growth potential in those markets.
- Higher production costs: Shinpoong Pharma may face challenges in maintaining competitive pricing due to higher production costs compared to some competitors.
Opportunities
- Increasing demand for healthcare: The global healthcare sector is witnessing substantial growth, presenting opportunities for Shinpoong Pharma to expand its market share.
- Emerging markets: There is great potential for the company to enter and establish a strong presence in emerging markets, where demand for pharmaceutical products is rising.
- Strategic partnerships and collaborations: Shinpoong Pharma can explore partnerships with research institutions or other pharmaceutical companies to enhance its product pipeline and market reach.
- Advances in technology: The company can leverage technological advancements to develop innovative drug delivery systems or enhance manufacturing processes, improving efficiency and competitiveness.
Threats
- Intense competition: The pharmaceutical industry is highly competitive, with numerous domestic and international players competing for market share.
- Stringent regulations: Regulatory changes or compliance requirements may pose challenges to Shinpoong Pharma's operations and product development.
- Intellectual property risks: The company may face risks related to patent infringements or the expiration of existing patents, leading to increased competition or loss of market exclusivity.
- Economic uncertainties: Fluctuations in global economic conditions can impact consumer spending patterns and access to healthcare, affecting the demand for pharmaceutical products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.